Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer genetic alterations and epigenetics control the malignant phenotype of tumor cells and the stroma. Synergistic oncogenic alterations may cooperatively dictate immunogenicity, level of infiltration by immune system cells, and response to immunotherapy in an epistatic fashion. The work of Skoulidis and colleagues shows that concomitant RAS and STK11/LKB1 mutations in non-small cell lung adenocarcinomas result in primary resistance to PD-1-based immunotherapy and poor T-cell infiltration. Cancer Discov; 8(7); 794-6. ©2018 AACRSee related article by Skoulidis et al., p. 822.

Original publication

DOI

10.1158/2159-8290.cd-18-0573

Type

Journal article

Journal

Cancer discovery

Publication Date

07/2018

Volume

8

Pages

794 - 796

Addresses

Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.

Keywords

Humans, Immunotherapy, Mutation, Proto-Oncogene Proteins p21(ras), Programmed Cell Death 1 Receptor, Adenocarcinoma of Lung, AMP-Activated Protein Kinase Kinases, Protein Serine-Threonine Kinases